痛风达标治疗
达标治疗(T2T)已在多种风湿病中应用并近期被提出用于痛风,但痛风T2T证据尚不充分,有观点建议保守对症治疗。证据提示长期不达标治疗与痛风发作、痛风石和结构损伤加重相关,进而导致生活质量下降和死亡风险增加。原文提出血尿酸目标为所有患者低于6 mg/dl(0.36 mmol/l),严重多关节或痛风石患者至少低于5 mg/dl(0.30 mmol/l)。
要点
- T2T已用于RA、脊柱关节炎、狼疮等风湿病,近期被提出用于痛风。
- 痛风T2T证据不足,有观点建议仅对症保守治疗。
- 长期不达标与发作、痛风石、结构损伤及生活质量下降和死亡相关。
核心结论
- 长期不达标治疗痛风与发作、痛风石和结构损伤加重相关,进而与生活质量下降和死亡相关。
- 原文提出所有痛风患者血尿酸目标低于6 mg/dl(0.36 mmol/l),严重多关节或痛风石患者至少低于5 mg/dl(0.30 mmol/l)。
研究设计与样本
- 原文为关于痛风达标治疗的综述,未报告系统检索范围。
主要发现
- T2T已在多种疾病中成功实施,并已提出用于RA、脊柱关节炎、狼疮及近期用于痛风。
- 不同疾病T2T证据水平不同,例如高脂血症为中等至高等证据。
- 痛风缺乏良好T2T证据,有观点建议仅对症保守治疗。
- 证据提示长期不达标治疗痛风与发作、痛风石和结构损伤加重相关,并与生活质量下降和死亡相关。
关键数值与推荐
- 所有痛风患者血尿酸目标低于6 mg/dl(0.36 mmol/l)。
- 严重多关节或痛风石患者血尿酸目标至少低于5 mg/dl(0.30 mmol/l)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出痛风缺乏良好T2T证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treat-to-target (T2T) approach has been successfully implemented in a number of diseases. T2T has been proposed for rheumatic diseases such as RA, spondyloarthritis, lupus, and recently for gout. The level of evidence for such approaches differs from one condition to the other (moderate to high for hyperlipidaemia, for example). Practice is based on the best available evidence at any time, and in absence of good evidence for T2T in gout, some suggest a conservative only-treat-symptoms approach. Evidence suggests that not treating gout to target in the long term is overall associated with worsening outcomes, such as flares, tophi and structural damage, which is associated to loss of quality of life and mortality. Different targets have been proposed for hyperuricaemia in gout; lower than 6 mg/dl (0.36 mmol/l) for all patients, at least <5 mg/dl (0.30 mmol/l) for patients with severe-polyarticular or tophaceous-gout.
引用
- Perez-Ruiz F, Moreno-Lledó A, Urionagüena I, et al. Treat to target in gout. Rheumatology (Oxford). 2018. PMID: 29272512. doi:10.1093/rheumatology/kex442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。